Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Gardiquimod is an agonist of human toll-like receptor 7 (TLR7), but not human TLR8, although it activates both porcine TLR7 and TLR8.1 At 0.5 to 2 µg/ml, it enhances the immunosuppressive activity of T regulatory cells.2 Gardiquimod is effective as a mucosal adjuvant for Norwalk virus-like particles and inhibits infection of macrophages and T cells by HIV-1.3,4 It inhibits proliferation and migration while inducing apoptosis in pancreatic cancer cells in vitro.5
WARNING This product is not for human or veterinary use.
1. Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod. Mol. Immunol. 45(11), 3238-3243 (2008).
2. Signaling through TLR7 enhances the immunosuppressive activity of murine CD4+CD25+ T regulatory cells. J. Leukoc. Biol. 87(1), 117-125 (2010).
3. An intranasally delivered Toll-
4. Gardiquimod: A toll-
5. Activation of Toll-